Healthcare Services

Neurofibromatosis Type 1 Market Forecast 2026–2035: How to Leverage Market Growth

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurofibromatosis type 1 market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Neurofibromatosis Type 1 Market size between 2026 and 2035?

The neurofibromatosis type 1 market has experienced robust expansion in recent years. It is projected to expand from $8.83 billion in 2025 to $9.68 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.6%. This historical growth is attributable to several key factors, including the prompt recognition of NF1 symptoms, the creation of effective pain management therapies, an increase in the diagnosis of plexiform neurofibromas, the implementation of surgical removal for tumors, and increasing public understanding of genetic counseling.

The neurofibromatosis type 1 market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $13.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This projected growth during the forecast period is primarily driven by factors such as an increasing demand for targeted nf1 therapies, greater investment in precision oncology, the broadening of treatment options for optic gliomas, enhanced access to advanced imaging technologies, and the creation of innovative gene-based treatments. Key trends expected within the forecast period encompass the expanded application of targeted therapy for tumor reduction, a heightened demand for early nf1 genetic testing, an increase in surgical interventions for tumor removal, the growing uptake of radiation therapy for optic gliomas, and an intensified emphasis on supportive care and counseling services.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp

Which Drivers Are Impacting Market Performance In The Neurofibromatosis Type 1 Market?

The market for neurofibromatosis type 1 (NF1) is anticipated to experience growth driven by spontaneous (de novo) mutations. A spontaneous (de novo) mutation is defined as a genetic change occurring for the initial time in an individual, originating from DNA replication errors or environmental influences, rather than being passed down through inheritance. The increase in spontaneous (de novo) mutations can be linked to factors such as elevated parental age, environmental elements like radiation and chemical exposure, and mistakes in DNA replication processes during cell division. Neurofibromatosis type 1 (NF1) itself contributes to these spontaneous (de novo) mutations because of the NF1 gene’s high mutation rate, often experiencing significant deletions, insertions, or point mutations during gametogenesis, resulting in new cases even without a prior family history. For example, in August 2023, a report from the US-based peer-reviewed journal, Molecular Biology and Evolution, indicated that 1.17 million autosomal and pseudoautosomal variants, with an average of 11,007 variants per offspring, successfully passed the Mendelian violation filter. Out of these, 534 suspected de novo mutations (DNMs) were found in POR and TVA families, not counting those shared between siblings. Consequently, spontaneous (de novo) mutation serves as a key driver for the expansion of the neurofibromatosis type 1 (NF1) market.

What Segment Types Are Examined In The Neurofibromatosis Type 1 Market?

The neurofibromatosis type 1 market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments

2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants

2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery

3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy

4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling

Which Trends Are Guiding The Evolution Of The Neurofibromatosis Type 1 Market?

Leading companies in the neurofibromatosis type 1 (NF1) market are concentrating on introducing innovative products, such as kinase inhibitors, to enhance targeted treatment and patient outcomes. A kinase inhibitor is a drug type that impedes the function of kinases, which are enzymes vital for transferring phosphate groups to proteins, thereby regulating various cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical industry company, obtained approval from China for Koselugo (selumetinib). This medication is intended for treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval broadens the selection of targeted treatment options for pediatric NF1 patients, improving disease management and overall quality of life. The introduction of Koselugo (selumetinib) in China aligns with the rising emphasis on precision medicine, presenting a non-surgical alternative for managing inoperable plexiform neurofibromas.

Who Are The Prominent Global Companies Shaping The Neurofibromatosis Type 1 Market Landscape?

Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, ReCode Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report

Which Region Is Projected To Lead The Neurofibromatosis Type 1 Market During The Forecast Period?

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurofibromatosis Type 1 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21230&type=smp

Browse Through More Reports Similar to the Global Neurofibromatosis Type 1 Market 2026, By The Business Research Company

Acoustic Neuroma Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795